BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
BioAge Labs, Inc.NASDAQ: BIOA
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 42.48M shares rose 18.5% year over year, ahead of the +7.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 17.6% from the prior quarter. Over 3 fiscal years it compounded at +1.7% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.5% holds above the trailing-twelve-month pace of +7.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 35.93M USD
- Year-over-year change
- +0.2%
- 3-year CAGR
- +1.7%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.93M | +0.2% |
| FY2024 | 2024-12-31 | 35.85M | +4.8% |
| FY2023 | 2023-12-31 | 34.2M | +0.1% |
| FY2022 | 2022-12-31 | 34.17M | — |
Weighted Avg Shares (Diluted) vs competitors
How BIOA compares with its peers on the latest reported figures
- BIOA's LTM Mar 2026 weighted avg shares (diluted) of 37.57M shares is the 9th highest of the 10 companies compared; the peer median is 90.28M shares.
- Its year-over-year change of +7.3% is the 7th highest of 9, against a peer median of +10.4%.
- Over three fiscal years its annual growth of +1.7% compares with a peer median of +15.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 298.22M | +210.7% | +300.6% | |
| LTM Mar 2026 | 225.47M | +9.3% | +15.5% | |
| LTM Mar 2026 | 167.44M | +37.0% | +15.3% | |
| LTM Mar 2026 | 94.61M | +90.6% | +51.6% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 80.03M | -5.4% | -0.7% | |
| LTM Mar 2026 | 56.58M | +3.1% | +20.7% | |
| LTM Mar 2026 | 53.53M | +11.4% | +24.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | 37.57M | +7.3% | +1.7% |
| LTM Mar 2026 | 37.34M | — | +5.7% | |
| Peer median (excluding BIOA) | 90.28M | +10.4% | +15.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.